Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity a
In this article, we will take a detailed look at Latest Insider Selling in April 2024: 10 Stocks to Watch. For a quick overview of the 5 such stocks, read our article Latest Insider Selling in April 2024: 5 Stocks to Watch. Wall Street analysts and wise investors often keep a close eye on insider buying and selling, […]
Rezdiffra Rezdiffra product image Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network CONSHOHOCKEN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Rezdiffra (resmetirom) is now available in
These businesses should see good times ahead.
James Daly, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 32,489 shares of the company on April 2, 2024, according to a recent SEC Filing.
Richard Levy, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 11,000 shares of the company on April 1, 2024, according to a recent SEC Filing.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focusing on the development and commercialization of novel therapies that address unmet needs in the treatment of liver and cardiovascular diseases, has reported a significant insider sell according to the latest SEC filings.
This liver-disease specialist might be significantly undervalued.
Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that’ll help you shed weight. Look at obesity drug stocks, for example. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Si
Both stocks are pretty risky, but one of them more so than the other.